February 13, 2019 / 2:15 PM / 2 months ago

BRIEF-Emerald, Lonza To Manufacture Cannabinoid-Derived Drug Candidate

Feb 13 (Reuters) - Lonza Group AG:

* EMERALD HEALTH PHARMACEUTICALS AND LONZA ANNOUNCE AGREEMENT FOR MANUFACTURING OF NOVEL CANNABINOID-DERIVED DRUG CANDIDATE

* PATENTED NEW CHEMICAL ENTITY DERIVED FROM SYNTHETIC CANNABIDIOL WILL INITIALLY TARGET MULTIPLE SCLEROSIS AND SCLERODERMA

* END-TO-END SOLUTION FOR PROCESS DEVELOPMENT AND MANUFACTURING OF API AND DOSAGE FORM WILL FACILITATE THE ADVANCEMENT OF CLINICAL DEVELOPMENT

* AGREEMENT WILL DEVELOP CGMP-STANDARD DRUG PRODUCT IN FORMATS THAT ARE EASY FOR PATIENTS TO TAKE Source text: bit.ly/2TN0lab Further company coverage: (Reporting by Berlin Speed Desk)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below